Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants With Normal Hepatic Function and With Hepatic Impairment, Cholestatic Liver Disease, NASH With Advanced Fibrosis
Latest Information Update: 12 Oct 2023
At a glance
- Drugs Saroglitazar (Primary)
- Indications Hepatic fibrosis; Liver disorders; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
- Focus Pharmacokinetics
- Sponsors Zydus Discovery DMCC
- 06 Aug 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 06 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Mar 2024.
- 03 Feb 2023 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.